“World Series” Trial: Verdict Against Mircera Gives Amgen ESA Market Hold
Executive Summary
While Roche is considering whether to appeal a jury verdict that its anti-anemia drug Mircera infringes Amgen's erythropoietin patents covering Epogen and Aranesp, Amgen is likely to retain its dominance over the $6 billion-plus erythropoiesis-stimulating agents market for some time
You may also be interested in...
Roche Plans At-Risk Launch Of Mircera, But Offers Amgen A 20% Royalty
Roche plans to move forward with an at-risk launch of Mircera (epoetin beta) if it does not receive a judicial ruling on its proposal to sell the anti-anemia drug at a reduced cost and pay Amgen a 20 percent royalty on sales. The company wants a court decision by the end of February
Roche Plans At-Risk Launch Of Mircera, But Offers Amgen A 20% Royalty
Roche plans to move forward with an at-risk launch of Mircera (epoetin beta) if it does not receive a judicial ruling on its proposal to sell the anti-anemia drug at a reduced cost and pay Amgen a 20 percent royalty on sales. The company wants a court decision by the end of February
Roche’s Mircera Clears FDA, But U.S. Launch Appears Stalled
FDA approved Roche's long-acting erythropoiesis-stimulating agent Mircera for the treatment of anemia associated with chronic renal failure in adults Nov. 14, but a near-term launch of the product appears unlikely given Amgen's legal hold on the market